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Abstract
Background: Clinically relevant glioma subtypes, such as the glioma-CpG island methylator phenotype (G-CIMP),
have been defined by epigenetics. In this study, the role of long non-coding RNAs in association with the poorprognosis G-CMIP-low phenotype and the good-prognosis G-CMIP-high phenotype was investigated. Functional
associations of lncRNAs with mRNAs and miRNAs were examined to hypothesize influencing factors of the aggressive
phenotype.
Methods: RNA-seq data on 250 samples from TCGA’s Pan-Glioma study, quantified for lncRNA and mRNAs (GENCODE v28), were analyzed for differential expression between G-CIMP-low and G-CIMP-high phenotypes. Functional
interpretation of the differential lncRNAs was performed by Ingenuity Pathway Analysis. Spearman rank order correlation estimates between lncRNA, miRNA, and mRNA nominated differential lncRNA with a likely miRNA sponge
function.
Results: We identified 4371 differentially expressed features (mRNA = 3705; lncRNA = 666; FDR ≤ 5%). From these,
the protein-coding gene TP53 was identified as an upstream regulator of differential lncRNAs PANDAR and PVT1
(p = 0.0237) and enrichment was detected in the “development of carcinoma” (p = 0.0176). Two lncRNAs (HCG11,
PART1) were positively correlated with 342 mRNAs, and their correlation estimates diminish after adjusting for either
of the target miRNAs: hsa-miR-490-3p, hsa-miR-129-5p. This suggests a likely sponge function for HCG11 and PART1.
Conclusions: These findings identify differential lncRNAs with oncogenic features that are associated with G-CIMP
phenotypes. Further investigation with controlled experiments is needed to confirm the molecular relationships.
Keywords: Long non-coding RNAs, Glioma, G-CIMP subtypes
Background
Glioma, a tumor of glial cells, is the most aggressive form
of tumor of the central nervous system (CNS). Historically glioma has been described by histologic features and
malignancy grading. Glioblastoma (GBM) is grade IV
disease, typically with necrotic regions, conferring poor
overall survival (15.5% at 2 years for adult GBM, 95% CI:
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15.1%–15.9%) [1, 2]. Diffuse gliomas, astrocytoma and
oligodendroglioma of grade 2 or 3, are characterized by
varying degrees of aggressiveness and extensive infiltrative growth in the surrounding CNS parenchyma [1, 2].
Recently, the World Health Organization (WHO) added
the presence of one of the recurrent point mutations in
the isocitrate dehydrogenase genes (IDH1 or IDH2) and
co-deletion of chromosomal arms 1p/19q to the glioma
diagnosis criteria [3]. Yet, even the refined molecular
diagnosis classifications do not fully explain the heterogeneous clinical phenotypes of these tumors.
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With recent advances in genomics, molecular subtypes
are able to be further refined. In glioma, characterization
of the epigenome by DNA methylation assay has been
useful in the stratification and integration of molecular and phenotypic features [3]. One such sub-classification, known as the CpG island methylator phenotype
(CIMP), is defined by genome-wide hypermethylation of
CpG Islands (CGI) and was first defined in the context
of colorectal cancer [4, 5]. The glioma-CIMP (G-CIMP)
subtype was first described by Noushmehr et al. [6] in
glioblastoma (GBM; Grade 4 glioma) and then in lowergrade gliomas (LGG; Grades 2, 3). Compared to G-CIMP
negative tumors, several studies found that G-CIMP
positive subtypes were typically associated with younger
patients and with IDH-mutant gliomas without 1p/19q
co-deletion [6, 7]. This IDH-mutant G-CIMP positive
subtype has now been further refined into two distinct
subgroups, G-CIMP-low (10% of IDH-mutant, 1p/19q
intact tumor) and G-CIMP-high (90% of IDH-mutant,
1p/19q intact tumors), with ‘low’ and ‘high’ designations determined by a low or high degree of DNA methylation, respectively. As opposed to the characteristically
higher survival rate of IDH-mutant glioma, G-CIMP-low
tumors have survival rates that are closer to that of GBM.
Even though the two G-CMIP subtypes have molecularly
distinct methylation patterns, factors driving the difference in prognosis are yet unknown. It is assumed that
DNA methylation patterns are associated with transcriptomic patterns, including non-coding RNAs. With recent
advances in RNA sequencing various RNA species can be
quantified (e.g., coding messenger RNA [mRNA], micro
RNA [miRNA;22–24 bp], and long non-coding RNA
[lncRNA, > 200 bp]). Among the RNA species, epigenetic
regulators such as long non-coding RNA (lncRNA) have
gained attention in recent years in cancer research.
LncRNAs are minimally 200-nucleotide RNA, with no
known translational capacity. They have drawn attention
due to their potential to regulate many cellular activities,
as well as gene expression, in biological and pathological processes. Acting as cellular address codes, lncRNAs
transfer proteins to their appropriate chromosomal location or fold them into higher order structures as target
recognition for chromatin remodeling. In glioma, lncRNAs have been associated with oncogenesis and prognosis [8, 9], such as in the recent global analysis of lncRNAs
in TCGA grade 2–4 gliomas that identified a panel of 64
lncRNAs associated with prognosis [10]. Among the specific lncRNAs studied, HOTAIR—a well-known, highlyexpressed lncRNA in breast cancer [11]—has been
associated with biogenesis and differentiation of gliomas
[10]. TALNEC2, a lncRNA highly expressed in GBMs and
with poor prognosis when silenced, inhibited cell proliferation and arrested the cells in the G1\S phase of the
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cell cycle in patient-derived glioma cell lines [12]. In addition, some newly discovered lncRNAs such as lncRNA
ASLNC22381 and KIAA0495 [9] have been found in glioma tissue and cell lines.
Since each of the glioma subtypes is clinically distinct,
understanding the role of associated epigenetic regulators could help to better distinguish between the groups.
Differential epigenetic regulators may also identify biological differences underlying the phenotypes or suggest
novel therapeutic targets. In this study we aimed to identify differentially expressed lncRNA between G-CIMPhigh and G-CIMP-low glioma, using RNA sequencing
data from the glioblastoma (GBM; Grade 4 glioma) and
lower grade glioma (LGG; Grades 2 and 3) arms of The
Cancer Genome Atlas (TCGA). As the functional roles
of most lncRNAs are poorly understood, we evaluated
lncRNA involvement by gene-set enrichment from an
available functional knowledgebase. Finally, we integrated lncRNA, miRNA, and mRNA expression through
correlation estimates to identify lncRNAs that may be
affecting transcription level changes in relationship to
miRNA by acting as a miRNA sponge.

Results
Sample details

A summary of the clinical and demographic data of the
TCGA G-CMIP cohort is represented in Table 1. These
cases are IDH mutant tumors, without 1p/19q co-deletion, by definition of the G-CMIP phenotype. As such,
the majority of the cases were under 40 years old at
diagnosis; most tumors had an astrocytomatous histology. Primary diagnosis for these tumors used the 2007
WHO diagnosis guidelines. The WHO 2016 diagnosis
was inferred from WHO grading (2/3 = Astrocytoma;
4 = GBM) and molecular features (IDH mutant, without
1p/19q co-deletion).
Association of lncRNA expression with G‑CIMP group

The comparison of RNA sequencing reads between
glioma subtypes G-CIMP-high and G-CIMP-low
identified 4371 differentially expressed (DE) features
(mRNA = 3705, lncRNA = 666) at a false discovery rate
of 0.05. Figure 1 shows a heatmap of the DE lncRNAs
between GCIMP-high and GCIMP-low groups. Here
the expression level is standardized per row with yellow
high and blue low. The rows are ordered by hierarchical
clustering of lncRNA expression. The majority of the 666
differential lncRNAs identified are highly expressed, with
a maximum fold change of expression in G-CIMP-low
tumors four times that of G-CIMP-high tumors.
The biological role of the DE lncRNA was explored
via pathway analyses. Of the 666 DE lncRNAs, 44 were
identified by lncRNA gene symbols in the QIAGEN
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Table 1 Patient characteristics for the 250 primary glioma
diagnoses in this study
G-CIMP High

G-CIMP Low

234

16

Under 40 (%)

149 (63.7%)

10 (62.5%)

Over 40 (%)

80 (34.2%)

6 (37.5%)

Unknown (%)

5 (2.1%)

0 (0.0%)

Male (%)

133 (56.8%)

7 (43.8%)

Female (%)

100 (42.7%)

9 (56.2%)

Unknown (%)

1 (0.4%)

0 (0.0%)

Oligodendroglioma

39 (16.7%)

0 (0.0%)

Oligoastrocytoma

74 (31.6%)

1 (6.2%)

Astrocytoma

118 (50.4%)

10 (62.5%)

Glioblastoma

2 (0.9%)

5 (31.2%)

Number of Cases
Age

Gender

WHO 2007 Histology

WHO Grade
2

111 (47.4%)

3

92 (39.3%)

8 (50.0%)

4

2 (0.9%)

5 (31.2%)

IDHmut – Astroctyoma

232 (99.1%)

11 (68.8%)

IDHmut – Glioblastoma

2 (0.9%)

5 (31.2%)

WHO 2016 Diagnosis

Knowledge Base and therefore available for analysis by
the Ingenuity Pathway Analysis tools. Set-enrichment
analyses identified protein-coding gene TP53 as an
upstream regulator of DE lncRNA PANDAR and PVT1
(p = 0.0237; Fig. 2a). In addition, “development of carcinoma” was identified as an enriched disease category
(Fig. 2b). Specifically, four oncology-related sets were
among the most enriched disease and biological function
categories (Table 2): ‘breast or colorectal cancer’ (9 DE
lncRNAs, p = 0.0049), ‘development of digestive organ
tumor’ (8 DE lncRNAs, p = 0.0122), ‘development of
carcinoma’ (9 DE lncRNAs, p = 0.0176), and ‘malignant
genitourinary solid tumor’ (8 DE lncRNAs, p = 0.0254).
A top constructed biological network associated with the
DE lncRNA list was associated with cell death and survival, cellular growth, and proliferation cellular development. This network was based on 6 DE lncRNAs with 29
genes from the IPA knowledgebase (enrichment score of
14; Fig. 2c). Network scores are based on the networkeligible molecules in the analysis. Scores are inversely
related to the probability of finding the selected networkeligible molecules in a given network by random chance.
Nomination of lncRNA as a miRNA sponge

Since less than 10% of the lncRNAs had known function in the pathway analysis we also used a data driven

Fig. 1 The heatmap of differentially expressed lncRNAs with a
fold change of at least 2. Here the expression level is presented as
standard deviations from the mean per lncRNA (row), with yellow
high, blue low, and black at the mean. The lncRNAs (rows) are ordered
by hierarchical clustering

approach to identify lncRNA functioning as miRNA
sponges. To identify lncRNA:miRNA:mRNA triplets
(sponge relationships), Spearman rank order correlation (rx,y) was estimated on expression levels between
each mRNA and DE lncRNA. As described in the
methods, the r x,y > 0.5 threshold resulted in 580 (lncRNAs) and 14,425 (mRNAs) selected. After filtering the
correlated pairs to only those with a common miRNA
target for the lncRNA and mRNA, 121,276 triplets
were constructed from 15 lncRNAs, 6777 mRNAs,
and 201 miRNAs. To assess if a triplet was likely
to reflect a sponge relationship, the partial correlation (rx,y|z) between each lncRNA and the correlated
mRNA was estimated, controlling for the predicted
common miRNA. The distribution of the influence of
miRNA on the lncRNA:mRNA correlation, specifically Sz = rx,y—rx,y|z, is plotted in Additional file 1: Fig
S1. Two miRNAs fell into the 99th percentile of this
Sz distribution: hsa-miR-129-5p, hsa-miR-490-3p.
Associated with these two miRNAs were two lncRNAs (HCG11, PART1), which were correlated with 290
(HCG11) and 114 (PART1) mRNAs, respectively, forming miRNA:lncRNA:mRNA trios. Thus, HCG11 and

Datta et al. J Transl Med

(2021) 19:182

Page 4 of 9

Fig. 2 Results from Ingenuity Pathway Analysis, a TP53 was identified as an upstream regulator of PANDAR and PVT1. b Differential lncRNAs
associated with development of a carcinogenic activity. c This gene–gene network includes 6 differentially expressed lncRNAs (PVT1, PANDAR,
FOXD2-AS1, CYTOR, CRNDE, and HOTAIRM1) and captures elements of cell growth, proliferation, survival and death
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Table 2 Biological functions from IPA knowledgebase that are enriched with DE lncRNAs
Disease and Biofunctions

P-values

Molecules

Breast or colorectal cancer

0.0049

C10orf25, CASC2, CRNDE, FOXD2-AS1, HCG11, HOTAIRM1, LINC00346, NORAD, PANDAR

Development of digestive organ tumor

0.0122

C10orf25, CASC2, CRNDE, EPB41L4A-AS1, FOXD2-AS1, HOTAIRM1, PCA3, PVT1

Development of carcinoma

0.0176

C10orf25, CASC2, CRNDE, CYTOR, EPB41L4A-AS1, FOXD2-AS1, HOTAIRM1, PCA3, PVT1

Colorectal carcinoma

0.0231

C10orf25, CRNDE, FOXD2-AS1, HOTAIRM1

Malignant genitourinary solid tumor

0.0254

CASC15, CASC2, CRNDE, HCG11, LINC00346, NORAD, PANDAR, PCA3

The p-values are calculated with Fisher exact test. Molecules listed here are those DE lncRNAs identified within the functional group being assessed

TP53 as a regulator of PANDAR and PVT1

Fig. 3 The network of sponge interaction between HCG11, PART-1,
hsa-miR-129-5p, hsa-miR-490-3p, and mRNAs (IPA knowledgebase
was used to restrict the figure to known mRNA targets for these 2
miRNAs). The network was drawn using the Cytoscape (v3.4.0) [35]

PART1 were nominated as sponges for hsa-miR-129-5p
and hsa-miR-490-3p, blocking their interaction with
342 unique mRNA; Fig. 3.

Discussion
In our investigation of the non-coding transcriptome
between G-CIMP-high and G-CMIP-low glioma subclasses, 666 differential lncRNAs were identified; some
of these lncRNA had previously been associated with
oncogenic activities in cancer. The expression levels of
the majority of these lncRNAs were lower in G-CIMPhigh tumors. The up-regulation in G-CIMP-low tumors
may relate to oncogenic activities leading to their
aggressive phenotype and poor survival. A previously
known relationship between TP53 (p53) and PVT1, as a
p53-induced target gene, was observed by examination
of upstream regulators of the differential lncRNA [13].
Further, we nominated two lncRNAs as having potential sponge activity for two microRNAs.

TP53 is a well-known gene for a tumor suppressor protein p53 that participates in diverse cellular functions
including cell cycle arrest, apoptosis, senescence, DNA
repair, and changes in metabolism. Mutation of TP53
is associated with a variety of human cancers including gliomas, and is found in 94 percent of IDH mutant,
1p/19q non-codeleted, glioma [14]. High expression of
PVT1, a long non-coding RNA located at chromosome
8a24.21, has been associated with several mutations of
TP53 in diffuse glioma [8]. In these data, the expression
of TP53 and PVT1 are positively correlated, with highest
expression of each occurring in GCIMP-low, see Additional file 2: Fig S2. Many studies have shown evidence of
carcinogenic activity of PVT1 in various cancers, such as
negatively modulating miRNA by acting as a competing
endogenous RNA or acting as a sponge to promote tumor
effects [15]. Of importance to glioma, PVT1 has been
implicated in regulating levels the proto-oncogene MYC
to promote tumorigenesis [16]. The role of MYC in glioma has been well established, both in vivo and in vitro,
such that MYC inhibition suppresses glioma formation,
restricts glioma cell proliferation and improves survival
[17]. The relationship between TP53 and PANDAR is
less understood, though human p53 [TP53] protein is
necessary for expression of human PANDA [PANDAR]
lncRNA. PANDAR is a promoter of CDKN1A antisense
DNA damage activated RNA and increased expression of
PANDAR has been indicated to predict poor prognosis
in cervical and gastric cancer[18, 19]. Recently, a study
published showed CDKN2A, a gene which belongs to
same family as CDKN1A, often deleted in G-CIMP-low
tumors as compared to G-CIMP-high [20]. While the
role of PANDAR has been evaluated in many cancers [21]
its association with glioma has not been studied.
Network focused on cell growth, proliferation, survival
and death

Cell death is one of the primary mechanisms studied in
cancer as disruption of this process can facilitate tumorigenesis, promote proliferation, and lead to resistance to
anticancer therapy. One of the top gene–gene networks
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generated from the IPA knowledgebase was associated
with the biological processes of cell death, survival, cell
growth and proliferation (Fig. 2c). This network was constructed from 6 DE lncRNAs (PVT1, PANDAR, FOXD2AS1, CYTOR CRNDE, HOTAIRM1) and 29 mRNAs that
interact directly (solid lines) or indirectly via an intermediate gene (dotted line). Among the interacting mRNAs,
the NOTCH1 gene’s role in glioma pathogenesis is well
established as it affects glioma tumorigenesis and maintenance. Several studies during recent years reported
dysregulated NOTCH signaling activity (NOTCH 1–4)
in human brain tumors [22]. In an extensive study on the
functional role of NOTCH1 in gliomas, it is observed
that NOTCH1 is involved in maintaining glioma cells in
an undifferentiated state, and its inhibition leads to cells
maturing into a less aggressive phenotype [22]. Also,
in the network (Fig. 2c) is MYC, a proto-oncogene that
encodes nuclear phosphoprotein control as a transcription factor for its target genes. As described above, we
see again the association between MYC and the PANDAR lncRNA.
Enrichment of oncogenic function

The biofunction “development of carcinoma” was one
of the top cancer-related enriched biofunctions (p-value
of 0.0176), with 8 DE lncRNAs: PVT1, CASC2, PCA3,
EPB41L4A-AS1, C10orf25, CYTOR, FOXD2-AS1, and
CRNDE. The increased expression of PVT1, CYTOR,
FOXD2-AS1, and CRNDE were seen in various cancers, similarly these lncRNAs were all up-regulated in
G-CIMP-low suggesting their more oncogenic activity leads to poor prognosis compared to G-CIMP-high.
While decreased expression has been seen in CASC2 and
PCA3 in cancer, these lncRNAs were down-regulated in
G-CIMP-low suggesting their tumor suppressor potential
[23–27]. Table 2 shows other carcinogenic functions from
the enrichment of DE lncRNAs with IPA knowledgebase.
Nominated lncRNA sponge activity

Research in many cancers has shown that lncRNAs can
regulate mRNA expression levels indirectly through
miRNA, by acting as a miRNA sponge. LncRNAs HCG11
and PART-1 were identified as potential sponges for the
miRNAs hsa-miR-490-3p and hsa-miR-129-5p (Fig. 3).
Previous studies [28] have shown lncRNA HCG11 to be
down-regulated in glioma tissues and cells, and this was
associated with a lower survival rate in glioma patients.
The observed mechanism is for lncRNA HCG11 to suppress growth of glioma was by acting with the miR-4425
to release MTA3. MiR-4425 is up-regulated in glioma tissues and a high expression of miR-4425 is associated with
an unfavorable prognosis in glioma [28]. Here we also
see decreased expression of HCG11 in our lower survival

Page 6 of 9

G-CIMP-low group and propose an interaction with
miR-490 and miR-129. LncRNA PART-1 has been shown
to have oncogenic activity in colorectal cancer [29], but
was identified as positively associated with GBM prognosis [30], such that decreased PART-1 predicted decreased
survival time [31]. In this study we observed that PART-1
expression was lower in the poor-prognosis G-CIMP-low
tumors, compared to G-CIMP-high tumors, which aligns
with the observed relationship in GBM. Neither lncRNA
HCG11 nor PART1 have been investigated for a relationship with hsa-miR-129-5p and hsa-miR-490-3p in glioma.
From prior research in lung and hepatocellular carcinoma, increased hsa-miR-490-3p has been implicated
in cell migration and cancer progression to metastatic
disease [32, 33]. Reduction of hsa-miR-490-3p through
sponge action of lncRNAs suggests a more favorable outcome, which we see in G-CMIP-high. In contrast, hsamiR-129-5p has been shown to inhibit the cell cycle and
induce apoptosis in glioma cell lines through inhibition
of NOTCH1 and mTOR signaling [34]. Reduction of
has-miR-129-5p through sponge action may thus allow
increased proliferation, which is counter to expectation
but dependent upon signaling pathways, so more study is
needed.

Conclusion
This in-silico study explores the potential influence of
non-coding RNA on the phenotypic difference between
the G-CMIP-high and G-CMIP-low subtypes of glioma.
The G-CMIP-low subtype is rare in primary glioma diagnosis, with less than 5% of all diffuse glioma diagnoses
identified as G-CMIP-low. However, prior work shows
that G-CMIP-high tumors may evolve to a G-CMIP-low
form as the disease progresses [36]. With this in-silico
study, we identified 666 lncRNAs that showed a difference in mean expression between the two G-CMIP subtypes. With the IPA knowledgebase, we were able to
propose the functional role of a subset of differential
lncRNAs related to progression to aggressive G-CIMPlow gliomas. In addition, we identified an upstream regulator, TP53, a well-known tumor suppressor gene which
can regulate two of the differential lncRNAs. Unfortunately, our study is not without limitation, as only 44
of 666 lncRNAs had biological function information in
the IPA knowledgebase. We were heartened that these
44 showed oncogenic relationships with genes known
to have a role in glioma, however, we realize that there
is much to be discovered among 622 lncRNAs with no
information in IPA. Beyond IPA, we also identified two
lncRNAs as potentially having miR-sponge activity,
HCG11 and PART-1. Each has prior evidence of an effect
on glioma prognosis, which increases our enthusiasm for
further study.
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Methods
Ethics statement

RNA-sequencing datafiles (TCGA Glioblastoma (GBMs)
and Lower-grade glioma (LGGs)) were obtained from
the Genomic Data Commons with appropriate approval
from dbGAP (#1904). They were acquired with a protocol
approved by the Henry Ford Health System institutional
review board (protocol #8718). The need for consent
was waived in this secondary data analysis since primary
identifiers were not provided by dbGAP.
Quantification of mRNA & lncRNAs

Aligned sequencing reads (BAM files) for TCGA GBMs
and LGGs, generated from the Illumina Hiseq platform,
were obtained from the Genomic Data Commons database (GDC) (March 2017). These Illumina raw reads
had been processed through the RNA-Seq standardized
pipeline at GDC. Briefly, the GDC pipeline first converted to fastq with ‘Biobambam’ and then re-aligned to
the GRCh38 reference genome per alignment guidelines
from International Cancer Genome Consortium (ICGC),
using the STAR aligner. A two-pass method was used for
alignment; first, splice-junctions were aligned separately
in each read group, then the read groups were merged to
obtain the final alignment in BAM format. Upon downloading these aligned BAM files, we quantified the read
counts for lncRNAs and protein-coding messenger RNA
(mRNA) against the reference annotation from GENCODE v28 [37]. This quantification was executed with
the ‘featurecount’ function, from the R Bioconductor
package ‘Rsubread,’ [38] which assigns mapped sequencing reads to genomic features. Two-hundred fifty samples
(see Table 1) and 37,281 features (22,583 mRNAs and
5729 antisense, 7845 lincRNA, 939 sense-intronic, 185
sense-overlapping lncRNA) were carried forward for further analysis.
Identifying differentially expressed sets of mRNA &
lncRNAs specific to subtypes

The quantified expression matrix (in terms of read
counts) for each sample was further filtered for low
count, based on counts per million (CPM). Features
with sum of expression values below the condition cutoff (CPM < 1) across conditions were removed. Normalization between cases was performed on the weighted
trimmed mean of the log2 expression ratios (TMM;
trimmed means of M-values) using the R Bioconductor
package NOISeqBio [39]. This normalization method
assumes that the majority of the RNA features are not
differential. After pre-processing, 24,178 features were
retained for analysis. The NOISeqBIO package was used
to identify differential expression per feature (mRNA and
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lncRNA) between G-CIMP-high and G-CIMP-low, considering the log2-ratio of the two conditions (M-value)
and the value of the difference between conditions
(D-value). A feature was identified as differential between
conditions if its corresponding M and D values are likely
to be higher than the expected noise, where the noise
distribution is obtained from comparing all sample pairs
within a condition. lncRNA were identified as differential
between the two groups if the false discovery rate (FDR)
was less than or equal to 5%. The differential mRNA and
lncRNA identified in this analysis are presented in Additional files 3 and 4.
Pathway analysis of differential lncRNA

LncRNAs that were differentially expressed between
G-CIMP-high and G-CIMP-low tumors were further
evaluated for biological functional interpretation with
Ingenuity’s IPA software knowledgebase [40]. The core
enrichment analysis was performed using all lncRNAs
from the Gencodev28 annotation, described above, as
the reference set for the Fisher’s exact test used to calculate enrichment p-values.
Integrative analysis of lncRNAs, miRNAs and mRNA
to predict miRNA sponge activity

In scenarios where a lncRNA is acting as miRNA sponge,
it is expected that the correlation between lncRNA and
mRNA expression will be positive. Further, the correlation between lncRNA and mRNA will be dependent on miRNA expression, such that it lessens when
the miRNA expression is considered. For this analysis,
TCGA miRNA-seq data were downloaded from the
Broad Firehose for 239 samples (G-CIMP-high = 228,
G-CIMP-low = 11). Data had been aligned and quantified by Broad, reporting log2 reads per million (RPM)
for 2588 miRNAs. Transcriptome-wide microRNA target prediction for each lncRNA and mRNA observed to
be differentially expressed between G-CIMP-high and
G-CIMP-low was obtained from MiRcode [41] annotation. Correlated lncRNA and mRNA pairs with a common miRNA target were retained for further analysis.
To assess whether a sponge relationship is likely within
each lncRNA:mRNA:miRNA trio, correlation between
the lncRNA and mRNA expression was estimated, alone
(rx,y; Spearman rank order correlation) and controlling
for the target miRNA expression (rx,y|z; Spearman rank
order partial correlation) [42]. The unconditional correlation was filtered to rx,y >  = 0.5, with p-value <  = 0.05.
Then a lncRNA was nominated as having a sponge function in the lncRNA:miRNA:mRNA trio if Sz = rx,y—rx,y|z
was high; here we use Sz > 0.2 [42].
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Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12967-021-02844-z.
Additional file 1: Fig. S1. The distribution of the influence of miRNA on
the lncRNA:mRNA correlation, Sz = rx,y—rx,y|z, is plotted. For RNA triplets
a reduction of correlation (Sz) of 0.2 or great were retained, in this study
0.2 is approximately the 99th percentile of the distribution of the S z
distribution.
Additional file 2: Fig S2. Scatterplot of the expression of TP53 and PVT1
in G-CIMP-high and G-CIMP-low tumors.
Additional file 3: Table S1. Differential_LncRNAs.

3.
4.
5.
6.
7.

Additional file 4: Table S2. Differential_mRNAs.
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